Grace Therapeutics Sets Virtual Annual Meeting for Sept. 12
Ticker: GRCE · Form: DEF 14A · Filed: Jul 28, 2025 · CIK: 1444192
| Field | Detail |
|---|---|
| Company | Grace Therapeutics, INC. (GRCE) |
| Form Type | DEF 14A |
| Filed Date | Jul 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: Proxy Statement, Corporate Governance, Annual Meeting, Director Election, Executive Compensation, Auditor Ratification, Pharmaceuticals
Related Tickers: GRCE
TL;DR
**GRCE's upcoming virtual annual meeting is a routine governance check, nothing to see here but standard board elections and auditor ratification.**
AI Summary
Grace Therapeutics, Inc. (GRCE) has filed a definitive proxy statement (DEF 14A) for its 2025 Annual Meeting of Stockholders, scheduled virtually for September 12, 2025, at 8:30 a.m. Eastern Time. The primary agenda includes the election of five director nominees for a one-year term expiring at the 2026 Annual Meeting. Stockholders will also vote on an advisory basis to approve the compensation of named executive officers, a common practice for transparency and investor feedback. Furthermore, the company seeks ratification for the appointment of KPMG LLP as its independent registered public accounting firm for the fiscal year ending March 31, 2026. The Board of Directors explicitly recommends a 'FOR ALL' vote for the director nominees and 'FOR' votes for both the executive compensation and auditor ratification proposals. This filing indicates a standard corporate governance cycle, with no immediate major strategic shifts or financial disclosures beyond the procedural aspects of an annual meeting. The company's business address is 103 Carnegie Center, Suite 300, Princeton, New Jersey 08540, and its phone number is 609-322-1602.
Why It Matters
This DEF 14A filing outlines Grace Therapeutics' standard corporate governance procedures, which are crucial for maintaining investor confidence and operational stability. For investors, the election of directors directly impacts the company's strategic direction and oversight, while the advisory vote on executive compensation provides a mechanism for shareholder input on leadership incentives. Ratifying KPMG LLP as the auditor ensures continued financial transparency and compliance, essential for market trust. In a competitive pharmaceutical landscape, robust governance practices can differentiate Grace Therapeutics and signal stability to employees, customers, and the broader market, especially as it operates in the highly regulated pharmaceutical preparations sector.
Risk Assessment
Risk Level: low — The DEF 14A filing primarily details routine corporate governance matters for the 2025 Annual Meeting, including director elections, executive compensation advisory vote, and auditor ratification. There are no indications of significant financial distress, strategic overhauls, or contentious proposals that would suggest a higher risk level. The Board's recommendations for all proposals further reduce the likelihood of unexpected outcomes.
Analyst Insight
Investors should review the proxy statement for details on director nominees' qualifications and executive compensation structures to ensure alignment with their investment thesis. Participate in the virtual meeting on September 12, 2025, to exercise voting rights and engage with management on governance matters, even though the proposals appear routine.
Key Numbers
- September 12, 2025 — Annual Meeting Date (Date stockholders will vote on key proposals)
- 5 — Director Nominees (Number of directors to be elected for a one-year term)
- March 31, 2026 — Fiscal Year End (Period for which KPMG LLP is appointed as auditor)
- 8:30 a.m. ET — Meeting Time (Specific time the virtual annual meeting will commence)
- 1 — Proposal No. 1 (Election of five director nominees)
- 2 — Proposal No. 2 (Advisory vote on named executive officer compensation)
- 3 — Proposal No. 3 (Ratification of KPMG LLP as independent auditor)
- 609-322-1602 — Business Phone (Contact number for Grace Therapeutics, Inc.)
- 001-35776 — SEC File Number (Unique identifier for Grace Therapeutics' SEC filings)
- 2025-07-28 — Filing Date (Date the DEF 14A was filed with the SEC)
Key Players & Entities
- Grace Therapeutics, Inc. (company) — Registrant and subject of the DEF 14A filing
- KPMG LLP (company) — Independent registered public accounting firm for fiscal year ending March 31, 2026
- September 12, 2025 (date) — Date of the 2025 Annual Meeting of Stockholders
- 8:30 a.m. Eastern Time (time) — Start time of the 2025 Annual Meeting
- 103 Carnegie Center, Suite 300, Princeton, New Jersey 08540 (address) — Business address of Grace Therapeutics, Inc.
- 609-322-1602 (phone_number) — Business phone number of Grace Therapeutics, Inc.
- March 31, 2026 (date) — End of fiscal year for which KPMG LLP is appointed
- five (number) — Number of nominees for director to be elected
- Delaware (state) — State of incorporation for Grace Therapeutics, Inc.
- 001-35776 (number) — SEC file number for Grace Therapeutics, Inc.
FAQ
What is the purpose of Grace Therapeutics' 2025 Annual Meeting?
The 2025 Annual Meeting of Grace Therapeutics, Inc. is being held to elect five nominees for director, approve on an advisory basis the compensation of named executive officers, and ratify the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026.
When and where will Grace Therapeutics' 2025 Annual Meeting be held?
Grace Therapeutics' 2025 Annual Meeting will be held virtually on September 12, 2025, at 8:30 a.m. Eastern Time. Stockholders can attend by visiting www.virtualshareholdermeeting.com/GRCE2025 and entering their 16-digit Control Number.
What are the Board's recommendations for the proposals at the Grace Therapeutics Annual Meeting?
The Board of Directors recommends that stockholders vote FOR ALL for Proposal No. 1 (election of directors) and FOR Proposals No. 2 (advisory vote on executive compensation) and No. 3 (auditor ratification).
Which accounting firm is Grace Therapeutics proposing to ratify for fiscal year 2026?
Grace Therapeutics is proposing to ratify the appointment of KPMG LLP as its independent registered public accounting firm for the fiscal year ending March 31, 2026.
How many directors are being elected at the Grace Therapeutics 2025 Annual Meeting?
Five nominees for director are being elected at the Grace Therapeutics 2025 Annual Meeting, each for a one-year term expiring at the 2026 Annual Meeting of Stockholders.
What is the significance of the advisory vote on executive compensation for Grace Therapeutics?
The advisory vote on executive compensation allows Grace Therapeutics' stockholders to express their opinion on the compensation paid to the company's named executive officers, providing valuable feedback to the Board of Directors on compensation practices.
What is the business address for Grace Therapeutics, Inc.?
The business address for Grace Therapeutics, Inc. is 103 Carnegie Center, Suite 300, Princeton, New Jersey 08540.
Is the Grace Therapeutics DEF 14A filing a preliminary or definitive proxy statement?
The Grace Therapeutics filing 0001140361-25-027456 is a Definitive Proxy Statement, as indicated by the checked box on the Schedule 14A.
What is the fiscal year end for Grace Therapeutics, Inc.?
Grace Therapeutics, Inc.'s fiscal year ends on March 31, as stated in the company data section of the filing.
How can stockholders submit questions during the Grace Therapeutics virtual Annual Meeting?
Stockholders will be able to submit questions during the live webcast of the Grace Therapeutics Annual Meeting by visiting www.virtualshareholdermeeting.com/GRCE2025 and entering their 16-digit Control Number.
Industry Context
Grace Therapeutics operates within the pharmaceutical preparations sector (SIC code 2834). This industry is characterized by extensive research and development, stringent regulatory oversight from bodies like the FDA, and significant competition from both established pharmaceutical giants and emerging biotech firms. Success often hinges on the ability to bring novel therapies through clinical trials and to market, requiring substantial capital investment and navigating complex intellectual property landscapes.
Regulatory Implications
As a pharmaceutical company, Grace Therapeutics is subject to rigorous regulatory scrutiny from agencies such as the FDA. Compliance with drug development, manufacturing, and marketing regulations is paramount. Any failure to adhere to these standards can result in significant fines, product recalls, or delays in drug approvals, directly impacting financial performance and market access.
What Investors Should Do
- Review the proxy statement for detailed information on director nominees and their qualifications.
- Consider the company's recommendation to vote 'FOR' Proposal No. 2, the advisory vote on executive compensation.
- Vote 'FOR' Proposal No. 3 to ratify the appointment of KPMG LLP as the independent auditor.
- Attend the virtual Annual Meeting on September 12, 2025, at 8:30 a.m. ET.
Key Dates
- 2025-09-12: 2025 Annual Meeting of Stockholders — Stockholders will vote on director elections, executive compensation, and auditor ratification.
- 2026-09-12: 2026 Annual Meeting of Stockholders — The term for the newly elected directors will expire at this meeting.
- 2025-07-28: Filing Date of DEF 14A — Indicates the official proxy statement has been submitted to the SEC, providing details for the upcoming annual meeting.
Glossary
- DEF 14A
- A definitive proxy statement filed with the SEC by a company, providing detailed information for shareholders regarding an upcoming annual meeting. (This document outlines the agenda, proposals, and board recommendations for Grace Therapeutics' 2025 Annual Meeting.)
- Named Executive Officers (NEOs)
- The top executive personnel of a company whose compensation is disclosed in SEC filings. (Stockholders will vote on an advisory basis to approve the compensation of these individuals.)
- Independent Registered Public Accounting Firm
- An external audit firm hired by a company to conduct an independent audit of its financial statements. (KPMG LLP is proposed for ratification to ensure the integrity of Grace Therapeutics' financial reporting for the fiscal year ending March 31, 2026.)
- Virtual Annual Meeting
- An annual meeting of shareholders conducted online, typically via a webcast, allowing remote participation. (Grace Therapeutics' 2025 Annual Meeting will be held virtually, requiring stockholders to access it online.)
Year-Over-Year Comparison
This filing is a standard DEF 14A for the 2025 Annual Meeting. As it pertains to corporate governance and procedural matters, it does not contain comparative financial data or strategic disclosures that would allow for a direct comparison to a previous filing in terms of revenue growth, margin changes, or new risks. The focus is on the upcoming shareholder votes for director elections, executive compensation, and auditor ratification.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on July 28, 2025 regarding Grace Therapeutics, Inc. (GRCE).